Max Planck Institute for Molecular Biomedicine

Blocking Abnormal Stem Cell Signal during Aging Lessens Related Bone Loss

Retrieved on: 
Wednesday, September 27, 2023

The study, led by researchers from NYU Grossman School of Medicine, found that blocking the signaling pathway, called Notch, in aging skeletal stem cells caused a "massive increase" in bone mass and restored lost bone-healing ability during aging.

Key Points: 
  • The study, led by researchers from NYU Grossman School of Medicine, found that blocking the signaling pathway, called Notch, in aging skeletal stem cells caused a "massive increase" in bone mass and restored lost bone-healing ability during aging.
  • The study results revolve around immature stem cells, which have the capacity to mature into more than one cell type.
  • Aging is known to come with loss of the ability of stem cells to become bone-making cells, with related skeletal deterioration among the most common causes of age-associated impairment.
  • "Our newly gained knowledge opens potential therapeutic avenues to overcome age-related bone loss by manipulating down-stream effectors for Notch signaling in these stem cells."

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Retrieved on: 
Monday, August 8, 2022

MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research.

Key Points: 
  • Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells.
  • Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018.
  • A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming.
  • His Stanford University lab pioneered the development of a new paradigm for treating aging and age-related diseases.

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Retrieved on: 
Monday, August 8, 2022

MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research.

Key Points: 
  • Sebastiano led development of the unique mRNA-based ERA (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored protein cocktails to rejuvenate targeted cells.
  • Sebastiano has served as chairman of Turn Bio's Scientific Advisory Board since he co-founded the company in 2018.
  • A Stanford School of Medicine faculty member, author of more than 50 scientific articles and frequent speaker at research conferences around the world, Sebastiano is prominent in the emerging field of cellular reprogramming.
  • His Stanford University lab pioneered the development of a new paradigm for treating aging and age-related diseases.